tradingkey.logo

electroCore, Inc.

ECOR

4.970USD

-0.025-0.50%
Close 09/19, 16:00ETQuotes delayed by 15 min
37.11MMarket Cap
LossP/E TTM

electroCore, Inc.

4.970

-0.025-0.50%

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
104 / 207
Overall Ranking
230 / 4720
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 4 analysts
Buy
Current Rating
21.080
Target Price
+322.02%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company. It provides non-invasive vagus nerve stimulation (nVNS) technology platform. The Company’s product categories include Handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headache, and Handheld, personal use consumer products utilizing nVNS technology to promote general wellness and human performance. Its products include gammaCore, Truvaga and TAC-STIM. Its gammaCore Sapphire, is a prescription medical device that is used for a variety of primary headache conditions. Its Truvaga is a personal use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com. The Company’s TAC-STIM product is not a medical device and is not intended to diagnose, cure, mitigate, prevent, or treat a disease or condition.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 193.09% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 25.18M.
Overvalued
The company’s latest PE is -3.12, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 3.54M shares, increasing 20.60% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 232.33K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.69.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.67, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 7.38M, representing a year-over-year increase of 20.23%, while its net profit experienced a year-over-year increase of 38.27%.

Score

Industry at a Glance

Previous score
6.67
Change
0

Financials

5.65

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data

Quality of Earnings

6.62

Operational Efficiency

7.32

Growth Potential

6.64

Shareholder Returns

7.11

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Healthcare Equipment & Supplies industry's average of 3.59. Its current P/E ratio is -3.14, which is 5.08% below the recent high of -3.29 and -36.26% above the recent low of -4.27.

Score

Industry at a Glance

Previous score
2.80
Change
1.2

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 104/207
No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.50, which is higher than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for electroCore, Inc. is 23.40, with a high of 25.00 and a low of 12.00.

Score

Industry at a Glance

Previous score
8.50
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts
Buy
Current Rating
21.080
Target Price
+322.02%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

118
Total
7
Median
8
Average
Company name
Ratings
Analysts
electroCore, Inc.
ECOR
4
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
31
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
29
1
2
3
...
24

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.41, which is lower than the Healthcare Equipment & Supplies industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 5.58 and the support level at 4.55, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.41
Change
-0.04

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(3)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
0.072
Neutral
RSI(14)
44.513
Neutral
STOCH(KDJ)(9,3,3)
45.593
Buy
ATR(14)
0.247
High Vlolatility
CCI(14)
19.086
Neutral
Williams %R
56.226
Sell
TRIX(12,20)
-0.633
Sell
StochRSI(14)
87.131
Overbought
Moving Average
Sell(4)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MA5
4.910
Buy
MA10
4.922
Buy
MA20
5.103
Sell
MA50
5.850
Sell
MA100
5.737
Sell
MA200
9.243
Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 47.26%, representing a quarter-over-quarter increase of 14.61%. The largest institutional shareholder is The Vanguard, holding a total of 232.33K shares, representing 3.06% of shares outstanding, with 18.88% increase in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Zhang (Tianyi)
734.64K
--
Theofilos (Charles Steve)
444.53K
--
Errico (Thomas J.)
246.25K
+4.23%
AWM Investment Company, Inc.
318.11K
+95.00%
The Vanguard Group, Inc.
Star Investors
232.33K
+37.54%
Goldberger (Daniel S)
142.23K
-21.64%
Renaissance Technologies LLC
Star Investors
178.43K
+35.39%
Happy Holstein Management, LLC
153.17K
--
MAZ Partners, L.P.
115.52K
-57.52%
1
2

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.04, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 0.35. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
3.04
Change
0
Beta vs S&P 500 index
0.35
VaR
+7.60%
240-Day Maximum Drawdown
+77.75%
240-Day Volatility
+107.38%
Return
Best Daily Return
60 days
+16.58%
120 days
+16.58%
5 years
+64.03%
Worst Daily Return
60 days
-29.15%
120 days
-29.15%
5 years
-29.15%
Sharpe Ratio
60 days
+0.45
120 days
-0.22
5 years
+0.08
Risk Assessment
Maximum Drawdown
240 days
+77.75%
3 years
+77.75%
5 years
+93.16%
Return-to-Drawdown Ratio
240 days
-0.40
3 years
+0.08
5 years
-0.17
Skewness
240 days
-0.77
3 years
-0.00
5 years
+1.43
Volatility
Realised Volatility
240 days
+107.38%
5 years
+102.13%
Standardised True Range
240 days
+17.78%
5 years
+17.73%
Downside Risk-Adjusted Return
120 days
-28.17%
240 days
-28.17%
Maximum Daily Upside Volatility
60 days
+104.63%
Maximum Daily Downside Volatility
60 days
+75.46%
Liquidity
Average Turnover Rate
60 days
+1.42%
120 days
+1.87%
5 years
--
Turnover Deviation
20 days
+69.41%
60 days
+41.75%
120 days
+86.76%

Peer Comparison

Healthcare Equipment & Supplies
electroCore, Inc.
electroCore, Inc.
ECOR
5.85 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
Insulet Corp
PODD
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
8.33 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stevanato Group SpA
Stevanato Group SpA
STVN
8.24 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Abbott Laboratories
Abbott Laboratories
ABT
8.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Transmedics Group Inc
Transmedics Group Inc
TMDX
8.01 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI